Drugs / BOLD-100
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07027423 | Mar 2026 → Jan 2027 expected | soft tissue sarcoma | University Health Network, Toronto | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04421820 | Aug 2020 → Jun 2026 overdue | cholangiocarcinoma, colorectal cancer, gastric cancer, malignant pancreatic neoplasm | Bold Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BOLD-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07027423 ↗ |
| Action | Inhibit | “BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells.” NCT04421820 ↗ |
| Modality | Small molecule | “BOLD-100 is a novel, targeted anti-cancer therapy which is an intravenously administered small molecule drug.” NCT04421820 ↗ |
| Route | Intravenous | “BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule.” NCT04421820 ↗ |